Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

This study has been completed.
Information provided by (Responsible Party):
Quark Pharmaceuticals Identifier:
First received: September 11, 2013
Last updated: October 14, 2015
Last verified: October 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2015
  Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)